Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines
- PMID: 31723741
- PMCID: PMC6745980
- DOI: 10.1097/HS9.0000000000000012
Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines
Conflict of interest statement
The authors have indicated they have no potential conflicts of interest to disclose.
References
-
- Burns R, Luengo-Fernandez R, Sullivan R, et al. Economic burden of malignant blood disorders across Europe: a population-based cost analysis. Lancet Haematol 2016; 3:e362–e370. - PubMed
-
- Quintiles IMS. The Impact of Biosimilar Competition in Europe; May 2017. QuintilesIMS, see http://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimi....
-
- Soledad Cabezón Ruiz (rapporteur), Report on EU options for improving access to medicines (2016/2057(INI)), European Parliament Committee on the Environment, Public Health and Food Safety. http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+REPORT+....
Publication types
LinkOut - more resources
Full Text Sources